Alkem Laboratories has inked an out-licensing deal with Stempeutics Research, a group company of Manipal Education and Medical Group (MEMG), for Stempeucel product for osteoarthritis indication. The out licensing deal comprises of upfront payment, royalties and various regulatory & sales based milestones payments.
Under this agreement, Alkem will get the exclusive marketing rights for Stempeucel in India for Osteoarthritis with Stempeutics manufacturing & supplying the product to Alkem. The product is expected to be available in Indian market by 2020 after undergoing the phase 3 Clinical trial in India, which is expected to commence in 2018.
Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.
